Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis.
The pharmacokinetics and dose response of recombinant human erythropoietin (rhEPO), administered intravenously and subcutaneously, were studied in chronic haemodialysis (HD) patients and in patients on chronic ambulatory peritoneal dialysis (CAPD). Furthermore, two products differing in the presence of albumin as preservative were compared. Although the pharmacokinetics differed after intravenous and subcutaneous administration, the dose response was the same. There is no statistically significant difference in the pharmacokinetics between the rhEPO in HD and CAPD, nor had the presence of albumin as preservative an influence on the pharmacokinetics.
Stockenhuber
F
F
1st Medical Clinic, University of Vienna, Austria.
Loibl
U
U
Gottsauner-Wolf
M
M
Jahn
C
C
Manker
W
W
Meisl
T F
TF
Balcke
P
P
D000328:Adult; D000418:Albumins; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011310:Preservatives, Pharmaceutical; D006435:Renal Dialysis
D000418:Albumins; D011310:Preservatives, Pharmaceutical; D004921:Erythropoietin